Higher TMB may predict response to immunotherapies in a tumor agnostic fashion, as evidenced by the approval of pembrolizumab in this setting, thus opening another potential BrM-focused therapeutic avenue for patients [50, 67]. This evidence concerns the gene SMARCA2 and neoplasm.